Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12274315 | 0.90 | BTK (0.53) | BTKCTSKGAANFKB1NFKB2 | |
| SCHEMBL19510113 | 0.85 | BTK (0.50) | BTKCTSKGAANFKB1NFKB2 | |
| SCHEMBL26361659 | 0.85 | BTK (0.50) | BTKCTSKGAANFKB1NFKB2 | |
| SCHEMBL14603687 | 0.83 | BTK (0.55) | BTKCTSKGAANFKB1NFKB2 | |
| SCHEMBL3702152 | 0.81 | BTK (0.61) | BTKCTSKGAANFKB1NFKB2 | |
| SCHEMBL10343938 | 0.81 | BTK (0.61) | BTKCTSKGAANFKB1NFKB2 | |
| SCHEMBL3702157 | 0.81 | BTK (0.61) | BTKCTSKGAANFKB1NFKB2 | |
| SCHEMBL1406894 | 0.81 | BTK (0.61) | BTKCTSKGAANFKB1NFKB2 | |
| SCHEMBL927559 | 0.81 | BTK (0.53) | BTKCTSKGAANFKB1NFKB2 | |
| SCHEMBL26135662 | 0.79 | BTK (0.51) | BTKCTSKGAANFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109422739-B | Deuterated indoleamine 2, 3-dioxygenase inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20200361919-A1 | DEUTERATED INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR AND APPLICATION THEREOF | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2020-11-19 | — | — | US | disclosed |
| US-20200361919-A1 | DEUTERATED INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR AND APPLICATION THEREOF | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2020-11-19 | — | — | US | disclosed |
| EP-3677581-A1 | DEUTERATED INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR AND APPLICATION THEREOF | Nanjing Transthera Biosciences Co. Ltd. (CN) | 2020-07-08 | — | — | EP | disclosed |
| EP-3677581-A1 | DEUTERATED INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR AND APPLICATION THEREOF | Nanjing Transthera Biosciences Co. Ltd. (CN) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046364-A1 | INHIBITORS OF RSV REPLICATION AND APPLICATIONS THEREOF | EMORY UNIVERSITY (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-2539335-B1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-21 | — | — | EP | disclosed |
| EP-2729458-B1 | PROCESSES FOR THE PREPARATION OF THIETANAMINE | SYNGENTA PARTICIPATIONS AG (CH) | 2016-10-05 | — | — | EP | disclosed |
| US-9006456-B2 | Processes for the preparation of thietanamine | SYNGENTA PARTICIPATIONS AG (CH) | 2015-04-14 | — | — | US | disclosed |
| US-20140206633-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2014-07-24 | — | — | US | disclosed |
| WO-2011104089-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-09-01 | — | — | WO | disclosed |
| EP-2213167-A1 | Anthranilamide derivatives and their use for the control of insects and acari | Syngenta Participations AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| EP-2213167-A1 | Anthranilamide derivatives and their use for the control of insects and acari | Syngenta Participations AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20100168066-A1 | NOVEL INSECTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100168066-A1 | NOVEL INSECTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100168066-A1 | NOVEL INSECTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| CN-101394742-A | Anthranilamide derivatives and their use for the control of insects and acari | SYNGENTA PARTICIPATIONS AG (CH) | 2009-03-25 | — | — | CN | disclosed |
| EP-1976385-A2 | ANTHRANILAMIDE DERIVATIVES AND THEIR USE FOR THE CONTROL OF INSECTS AND ACARI | Syngeta Participations AG (CH) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007080131-A2 | ANTHRANILAMIDE DERIVATIVES AND THEIR USE FOR THE CONTROL OF INSECTS AND ACARI | SYNGENTA PARTICIPATIONS AG (CH) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007080131-A2 | ANTHRANILAMIDE DERIVATIVES AND THEIR USE FOR THE CONTROL OF INSECTS AND ACARI | SYNGENTA PARTICIPATIONS AG (CH) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168066-A1 | NOVEL INSECTICIDES | DDT, ACHE, CYP4F11 | BTK 2449/4885CTSK 3159/4885GAA 2476/4885 |
| US-20140206633-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | CYP1A2, CHRM1, CYP1A1 | BTK 2514/4885CTSK 3965/4885GAA 3222/4885 |
| US-20200361919-A1 | DEUTERATED INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR AND APPLICATION THEREOF | IDO1, IDO2, INMT | BTK 3101/4885CTSK 2647/4885GAA 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.